https://www.prnewswire.com/news-releases/ionis-presents-positive-phase-2-data-from-open-label-extension-study-of-donidalorsen-at-2022-acaai-annual-meeting-301676308.html
0
0
Ionis presents positive Phase 2 data from open label extension study of donidalorsen at 2022 ACAAI Annual Meeting - PR Newswire
11/13/22 at 6:01pm
Organization
PRNewswire
Authors
Details
41 words
Summarize
Business & Industrial Ionis extension study donidalorsen PRNewswire Nasdaq IONS Phase 2
/PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today presented positive results from a Phase 2 open-label extension (OLE) study evaluating the...
Create an account or login to join the discussion